Kifunensine compromises lung endothelial barrier function

Microvasc Res. 2020 Nov:132:104051. doi: 10.1016/j.mvr.2020.104051. Epub 2020 Jul 28.

Authors

Mohammad Shohel Akhter¹, Khadeja-Tul Kubra¹, Mohammad A Uddin¹, Nektarios Barabutis²

Affiliations

¹ School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, United States of America.
² School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, United States of America. Electronic address: barabutis@ulm.edu.

PMID: 32730762
DOI: 10.1016/j.mvr.2020.104051

No abstract available

Keywords: Acute Lung Injury; Acute Respiratory Distress Syndrome; Inflammation.

Publication types

Letter
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Alkaloids / toxicity*
Capillary Permeability / drug effects*
Cardiac Myosins / metabolism
Cells, Cultured
Cofilin 1 / metabolism
Electric Impedance
Endothelial Cells / drug effects*
Endothelial Cells / metabolism
Endothelial Cells / pathology
Humans
Lung / blood supply*
Myosin Light Chains / metabolism
Phosphorylation
Pulmonary Artery / drug effects*
Pulmonary Artery / metabolism
Pulmonary Artery / pathology
Unfolded Protein Response / drug effects*

Substances

Alkaloids
CFL1 protein, human
Cofilin 1
Myosin Light Chains
myosin light chain 2
kifunensine
Cardiac Myosins